Towards an integrated model for breast cancer etiology: The crucial role of the number of mammary tissue-specific stem cells by Trichopoulos, Dimitrios et al.
13 IGF = insulin-like growth factor.
Available online http://breast-cancer-research.com/content/7/1/13
Introduction
An etiologic model should explain as many of the
epidemiologic characteristics of a disease as possible, as
well as the results of analytical epidemiologic studies with
specific objectives. In this regard, no issue has been
studied as intensively as breast cancer etiology, and
several comprehensive reviews of the epidemiology and
etiology of this disease have been published.
Breast cancer epidemiology
The established epidemiologic characteristics of breast
cancer are indicated below [1–4]. Breast cancer is at
least 100 times more common among women than among
men. The incidence of the disease has apparently
increased throughout the world during the past century,
even before the widespread application of mammographic
screening programs, and it is generally higher among
women of higher socioeconomic status and among urban
rather than rural residents. Caucasian women in the
western world have a considerably higher breast cancer
risk than do Asian women in China or Japan. Breast
cancer incidence increases with age throughout the
world, but the slope of the increase decreases after the
menopause. An earlier age at menarche and a later age at
menopause are associated with increased risk, whereas,
for a given age at menopause, bilateral oophorectomy
conveys more protection than naturally occurring
menopause.
In general terms, pregnancies convey protection, but in a
complex way. Irrespective of the woman’s age, a
pregnancy imparts a short-term increase in breast cancer
risk followed by a substantial long-term reduction in this
risk. Hence, the earlier the age at first full-term pregnancy,
the more prolonged is the subsequent long-term
protection. After the age of about 35 years, a first
pregnancy actually increases breast cancer risk because
the short-term risk increase exceeds the subsequent risk
reduction. Additional full-term pregnancies have similar but
quantitatively much weaker effects, whereas spontaneous
or induced abortions do not appear to affect breast
cancer risk. Prolonged lactation conveys some protection
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Abstract
Perinatal events and conditions, notably birth weight, are associated with breast cancer risk in
offspring, and correlates of mammary gland mass are predictors of breast cancer risk. These findings
may be interpreted as indicating that high levels of estrogens and components of the insulin-like
growth factor system during pregnancy favour the generation of mammary tissue-specific stem cells,
and that the number of these cells, which is positively associated with mammary gland mass, is an
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affect birth weight.
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but the effect is modest and may be more pronounced
among premenopausal women.
Height is positively associated with breast cancer risk
[5,6], whereas obesity is inversely related to this risk
among premenopausal women [7] but positively among
postmenopausal women [8,9]. A high-density mammogram
(≥75% of total breast area with dense mammographic
appearance) indicates an almost fourfold risk in
comparison with a low-density mammogram (≤25% of
total breast area with dense mammographic appearance)
[10,11].
Several exogenous factors have been studied in relation to
breast cancer, but the evidence appears adequate for only
a few [3]. Ionizing radiation is an established cause of the
disease but it is of limited quantitative importance,
whereas most studies indicate that consumption of
alcoholic beverages may slightly increase breast cancer
risk. It has been reported that intake of fruits, vegetables
and olive oil, as well as physical activity, may reduce
breast cancer risk, but the evidence is inconclusive and
points to weak effects at most. Exposure to
organochlorines or electromagnetic fields has not been
shown to be related to breast cancer. Current or recent
use of oral contraceptives slightly increases the risk for
breast cancer [12], whereas long-term use of replacement
estrogens, with or without progestins, may substantially
increase breast cancer risk [13–15].
Mutations in BRCA1 and  BRCA2, as well as highly
penetrant mutations in genes such as p53, CHEK2, and
PTEN/MMAC1, account for a large proportion of familial
breast cancers, but they account for a small proportion of
all breast cancers [16]. Among individuals with
apparently sporadic breast cancers, very few carry
mutations that are known to be strongly related to the
disease. It has long been known that there is a familial
aggregation of breast cancer [17] that cannot be fully
explained in terms of the indicated major genes. Thus, it is
possible that other genes associated with a more
moderate influence on breast cancer risk are also
involved, perhaps modifying the effects of other risk
factors for breast cancer [18].
Most prospective studies on endogenous hormones in
relation to breast cancer risk have been undertaken
among postmenopausal women because of difficulties
relating to menstrual timing of sampling among
premenopausal women, the relative frequency of
postmenopausal and premenopausal breast cancer, and
the age spectrum of most established cohorts. Among
postmenopausal women, virtually every hormone examined –
with the notable exception of adiponectin, which has only
been evaluated through case–control designs [19,20] – is
positively associated with breast cancer risk [3,21,22].
The list includes total and free estradiol, estrone and
estrone sulphate, androstenedione, dehydroepiandros-
terone and dehydroepiandrosterone sulphate, testos-
terone, and prolactin. Most reported studies conducted in
premenopausal women have been of the case–control
design and tend to support a positive association between
estrogens and breast cancer risk [3,23,24]. In both
prospective and retrospective studies conducted in
premenopausal women, significant associations have
been found between blood insulin-like growth factor
(IGF)-1 and breast cancer risk [25].
The etiologic model
Our views on the etiology of breast cancer were
presented in several reports [1,26–32] and the main
points are as follows. First, the likelihood of breast cancer
occurrence depends on the number of mammary tissue-
specific stem cells, which is determined early in life,
notably  in utero or during immediate postnatal life.
Second, in adult life all growth-enhancing mammotropic
hormones, in conjunction with their receptors, affect the
likelihood of retention of cells with spontaneous somatic
mutations, as well as the rate of expansion of initiated
clones. Finally, although a pregnancy stimulates the
replication of already initiated cells, it conveys long-term
protection through differentiation of a large fraction of the
mammary tissue-specific stem cells.
Breast cancer epidemiology under the early
life modulation of mammary stem cells model
In this part of the review we examine the extent to which
the etiological model we present accommodates the
epidemiology of breast cancer. Parts of this discussion are
based on an earlier report [1], in which many of these
issues were considered in detail.
First postulate
The evidence linking mammary gland mass, as distinct
from breast size, to breast cancer risk is strong.
Mammographic density is a powerful predictor of breast
cancer risk, and this density is strongly associated with
mammary gland mass [10,11]. Small breasted women
who were motivated to undergo augmentation
mammoplasty, and whose mammary gland mass had to be
small, were found in most studies to have reduced breast
cancer risk [33,34]. Mammary gland mass, which is likely
to reflect the total number of mammary cells and be
correlated with the number of mammary stem cells, can
also accommodate several breast cancer risk factors,
including the following: breast cancer risk is higher among
Caucasian than among Asian women; it is higher in
women of higher than in those of lower socioeconomic
status; and it is higher in women residing in urban than in
women residing in rural areas (in each of these
comparison sets, the women in the first group are
generally taller and bigger, independently of obesity) [1].15
The postulate is also in accordance with the positive
association between adult height and breast cancer risk, an
association that has long been known but generally under-
appreciated [1,5,6,28], as well as the repeatedly supported
association between birth size and breast cancer risk
[35–37]. This postulate may also underlie the secular
increase in breast cancer incidence in many populations
during the past century (a period during which growth
accelerated and attained height increased in these
populations) [31], the higher breast cancer risk among
leaner premenopausal women (who are known to have
higher density mammographic pattern) [10], and the
apparent protective effect of anorexia nervosa against breast
cancer [38]. Last, but by no means least, the strikingly higher
breast cancer risk among women than among men even in
later life is best explained by the correspondingly higher
mammary gland mass among women than among men,
because estrogen production in later life is not substantially
different between the two sexes [28].
Second postulate
The traditional view on breast cancer implicates estrogens
in general, or specific categories of estrogens, or
progesterone, prolactin, or other hormones, including IGF,
as central to the etiology of the disease. The second
postulate of the etiological model we propose deviates
slightly from the traditional view in that it accepts that all
growth enhancing and mammotropic hormones are
involved in one or more stages in the long process that
leads to clinical breast cancer. An important implication of
this postulate is that, in studies evaluating several of these
hormones, it would be worth considering assessing their
additive consequences for breast cancer risk (e.g. by
expressing each of these hormones in terms of the
corresponding standard deviates). It is not necessary for
each hormone to have a quantitatively similar breast
cancer risk implication per standard deviate, and the
proposed model’s third postulate accommodates any role
that may be played by differential hormone receptor
expression [39,40].
This postulate accommodates several breast cancer risk
factors: the inflection of breast cancer incidence after
menopause; the increased risk for this disease with earlier
menarche and later menopause; the protective effect of a
surgical menopause with oophorectomy; the transient
increase in risk following a pregnancy; the increased risk
among overweight postmenopausal women and the
positive association with breast cancer risk of alcohol
drinking (which tends to increase estrogen levels);
hormone replacement therapy; and – however weakly –
oral contraceptives.
Third postulate
The number of mammary gland cells at risk for
transformation, and, thus, that confer breast cancer risk, is
reduced through the process of terminal differentiation that
takes place mostly after the occurrence of the first full-term
pregnancy and, to some extent, after the occurrence of
subsequent pregnancies and lactation [41]. When the first
full-term pregnancy occurs at an early age, malignant
transformation is likely to have already been initiated in only
few mammary cells, which could be boosted by the many
fold increases in mammotropic and growth enhancing
hormones that accompany a pregnancy. The later the age
at first full-term pregnancy, the higher the number of
already initiated cells and the more limited the protection.
Beyond the age of 35 years or so, the transient increase in
breast cancer risk that accompanies a pregnancy
overshadows the protection conveyed by the terminal
differentiation of immature mammary cells. In addition to the
substantial protection conveyed by an early full-term
pregnancy, the more limited protection conveyed by
subsequent pregnancies and by lactation, and the
crossover in the effect of a first pregnancy around the age
of 35 years, the third postulate also accommodates what
was largely thought to be an enigma, namely that breast
cancer risk is higher among parous than among nulliparous
women of premenopausal age.
The three postulates: general comments
It should be noted that this model relying on the three
indicated postulates is not refuted by the fact that
populations at low risk for breast cancer (e.g. native
Chinese populations) have higher levels of most
pregnancy – or even adult life – hormones [42]. It is
plausible that, in striking ecologic contrasts (e.g. between
native Chinese and Caucasian populations), pregnancy
growth hormones tend to increase in order to compensate
for physically constrained fetal growth [31], and the
perinataly programmed higher levels of these hormones
could track throughout adult life. Also, the model is not
refuted by the absence of association of breast cancer
with induced abortions and exposure to organochlorines
or magnetic fields, because none of these exposures has
been documented to affect the factors and processes that
are involved in the three postulates [43]. The possible, but
undocumented, effects of diet and physical activity on
breast cancer risk could be explained in terms of the first
or the second postulate, although there is inadequate
evidence as to whether these two variables affect either
the number of mammary cells at risk or the levels of
circulating mammotropic and growth hormones. Finally,
the general positive association between age and breast
cancer risk, and the established role of ionizing radiation
and some major genes in the causation of a small fraction
of breast cancer cases can be explained in terms of
general carcinogenesis theory.
The model, the evidence, and the predictions
The model we outline above goes beyond being a simple
hypothesis. It has evolved during the past 15 years to
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accommodate most of the existing and emerging empirical
evidence. Also, the proposed model is not a collation of
three independent postulates that happen to cover
different aspects of the epidemiology of breast cancer.
The three postulates represent stages in a single biologic
process that points to the number of mammary tissue-
specific stem cells as the core determinant of breast
cancer risk. The first postulate focuses on the perinatal
period, when stem cells in general, and tissue-specific
stem cells in particular, are generated. The second
postulate concentrates on pre-initiation and post-initiation
growth factors that modulate the number of mammary
stem cells at risk and the growth of the initiated clones.
The third postulate explains how cells at risk are removed
through terminal differentiation or related processes. The
whole model is in agreement with the results of theoretical
exercises and speculations undertaken long ago by
several authors, including Moolgavkar and colleagues
[44].
Two important questions emerge from what has been
presented above. How can this model be further
evaluated, and is this suggested process specific for
breast cancer or does it concern human carcinogenesis in
general? The most critical evaluation may rely on a design
proposed by Hsieh and coworkers [45], who are
evaluating whether mammotropic and growth hormones
are associated with cord blood stem cells. Another
approach was taken by Ekbom and colleagues (personal
communication), who are evaluating whether immediate
postnatal growth, a period during which the number of
stem cells is likely to be modulated, is associated with
breast cancer risk in offspring. Useful results may also
emerge from a unique follow-up study of women born to
mothers who had taken diethylstilbestrol during their
pregnancies [46]. It would also be useful to confirm the
findings of a study [47] that reported that perinatal
characteristics indicative of high breast cancer risk predict
mammographic patterns that are associated with high
breast cancer risk in adult life.
It is not implausible that a process similar to that outlined
in the proposed model may also apply to other forms of
human cancer [30], and, indeed, there have been reports
that birth weight may have associations with other types of
childhood and adult onset cancer [48,49]. It may be that
the positive association between birth weight and cancer
risk is stronger for the mammary gland than for other
organs, because hormones critical for breast cancer risk,
including estrogens and IGF-1, are also critical
determinants of birth weight. Alternatively, it may be that
the number of tissue-specific stem cells is more intimately
linked to cancer in the mammary gland than to cancer in
other organs, because mammary gland is exceptional in
that it is not fully developed at birth [50] and is regularly
stimulated by hormones during the menstrual cycle.
Conclusion
High levels of pregnancy estrogens and components of
the IGF system during the perinatal period favor the
generation of mammary tissue-specific stem cells, and the
number of these cells, which is positively associated with
mammary gland mass, is an important determinant of
breast cancer risk. A proposed three-tier model
accommodates essentially all of the known risk factors for
breast cancer and provides a plausible biologic
mechanism for human breast carcinogenesis.
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